NICE needs more info on Pradaxa before it can win warfarin replacement race
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, wants more information on the cost-effectiveness of Boehringer Ingelheim's Pradaxa (dabigatran etexilate) before it decides whether to recommend it for preventing stroke and systemic embolism in patients with atrial fibrillation. Companies with potential competitors in the warfarin replacement market will be paying close attention to the type of scrutiny their products will come under from payers.